First patient was dosed at Samsung Medical Center in Seoul, South Korea; a second at Moffitt Cancer Center in Tampa, FloridaGlobal multi-site study includes locations in U.S., Korea, the UK, Spain, and FranceStudy aims to confirm lirafugratinib’s potential efficacy among patients with FGFR2 fusion/rearrangement independent of tumor type FORT LEE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that the first patients were dosed in its global Phase 2 study of lirafugratinib in non-cholangiocarcinoma (CCA) solid tumors with FGFR2 fusion or rearrangement.